Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Stock Information for Aclarion Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aclarion Inc.

Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
Aclarion CEO Brent Ness to Attend LSI USA 2026
Aclarion Publishes 2026 Shareholder Letter from the Chairman
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
Aclarion Provides 2025 Update and 2026 Corporate Outlook
Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.